<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Continuity of Care Document</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body><h1 class="h1center">Continuity of Care Document</h1><table class="header_table"><tr><td class="td_header_role_name"><span class="td_label">Patient</span></td><td class="td_header_role_value">DOMINICK MANNELLINO</td></tr><tr><td class="td_header_role_name"><span class="td_label">Date of birth</span></td><td class="td_header_role_value">October 3, 1946 </td></tr><tr><td class="td_header_role_name"><span class="td_label">Current Gender</span></td><td class="td_header_role_value">Male</td></tr><tr><td class="td_header_role_name"><span class="td_label">Race(s)</span></td><td class="td_header_role_value"><ul style="list-style: none;list-style-position:outside;margin:0;padding:0; "><li>White</li></ul></td></tr><tr><td class="td_header_role_name"><span class="td_label">Ethnicity</span></td><td class="td_header_role_value"><ul style="list-style: none;list-style-position:outside;margin:0;padding:0; "><li>Not Hispanic or Latino</li></ul></td></tr><tr><td class="td_header_role_name"><span class="td_label">Language(s)</span></td><td class="td_header_role_value"><ul style="list-style: none;list-style-position:outside;margin:0;padding:0; "><li>English (Preferred)</li></ul></td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value"> Home Address:<br/>9440 POINCIANA PL APT 117<br/>DAVIE, FL 33324, US<br/><br/> Home Address:<br/>9440 POINCIANA PL APT 117<br/>DAVIE, FL 33324<br/>Expiration Date: June 26, 2024, 00:00:00  <br/><br/> Home Address:<br/>9440 POINCIANA PL 117 APT 117<br/>DAVIE, FL 33324<br/>Expiration Date: June 26, 2024, 00:00:00  <br/><br/> Home Address:<br/>9440 POINCIANA PL APT 117<br/>DAVIE, FL 33324<br/>Expiration Date: June 26, 2024, 00:00:00  <br/><br/>Primary Home Phone:  +1-(954)473-0829<br/>Work Phone:  +1-(999)999-9999<br/>Email:  DONNYD1946@GMAIL.COM<br/></td></tr><tr><td class="td_header_role_name"><span class="td_label">Patient IDs</span></td><td class="td_header_role_value">W230887 2.16.840.1.113883.3.1110.6.1.6.1.8.1<br/></td></tr></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Document Id</span></td><td class="td_header_role_value">89ed3779-b681-4f37-b8e9-f8c1597fe86b 2.16.840.1.113883.3.1110</td></tr><tr><td class="td_header_role_name"><span class="td_label">Document Created:</span></td><td class="td_header_role_value">August 30, 2024, 20:13:46 +0000 </td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Performer (primary care physician)</span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">FRYDMAN JARROD M </td></tr><tr><td class="td_header_role_value internal_format"/></tr></tbody></table></td></tr><tr><td class="td_header_role_name"><span class="td_label">Performer (primary care physician)</span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">Frydman Jarrod DO </td></tr><tr><td class="td_header_role_value internal_format"/></tr></tbody></table></td></tr><tr><td class="td_header_role_name"><span class="td_label">Performer </span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">FRALAR </td></tr><tr><td class="td_header_role_value internal_format"/></tr></tbody></table></td></tr><tr><td class="td_header_role_name"><span class="td_label">Performer </span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">Bierzynski Adam MD </td></tr><tr><td class="td_header_role_value internal_format"/></tr></tbody></table></td></tr><tr><td class="td_header_role_name"><span class="td_label">Performer </span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">Salerno Peter DO </td></tr><tr><td class="td_header_role_value internal_format"/></tr></tbody></table></td></tr><tr><td class="td_header_role_name"><span class="td_label">Performer </span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">Amin Harshad V MD </td></tr><tr><td class="td_header_role_value internal_format"/></tr></tbody></table></td></tr><tr><td class="td_header_role_name"><span class="td_label">Performer </span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">BACHAR DAHMAN </td></tr><tr><td class="td_header_role_value internal_format"/></tr></tbody></table></td></tr><tr><td class="td_header_role_name"><span class="td_label">Performer </span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">BRAIS </td></tr><tr><td class="td_header_role_value internal_format"/></tr></tbody></table></td></tr><tr><td class="td_header_role_name"><span class="td_label">Performer </span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">Lugo Ernesto DO </td></tr><tr><td class="td_header_role_value internal_format"/></tr></tbody></table></td></tr><tr><td class="td_header_role_name"><span class="td_label">Performer </span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">Satija Sameer MD </td></tr><tr><td class="td_header_role_value internal_format"/></tr></tbody></table></td></tr><tr><td class="td_header_role_name"><span class="td_label">Performer </span></td><td class="td_header_role_value"><table class="header_table internal_format"><tbody><tr><td class="td_header_role_value internal_format">5OBC5205 </td></tr><tr><td class="td_header_role_value internal_format"/></tr></tbody></table></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Author</span></td><td class="td_header_role_value">dbMotion 1.0.0.0</td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value"> Home Address:<br/>1 Park Plaza<br/>Nashville, TN 37203, US<br/><br/>Tel:  +1-(615)344-9551<br/></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Information recipient:</span></td><td class="td_header_role_value">HCA HealthCare. If additional information is needed, contact Health Information Management at (844) 481-0278 or at PARA.HSC.MEDRECROIFAX@PARALLON.COM</td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value"> Home Address:<br/>1 Park Plaza<br/>Nashville, TN 37203, US<br/><br/>Tel:  +1-(615)344-9551<br/></td></tr></tbody></table><table class="header_table"><tbody><tr><td class="td_header_role_name"><span class="td_label">Document maintained by</span></td><td class="td_header_role_value">HCA HealthCare. If additional information is needed, contact Health Information Management at (844) 481-0278 or at PARA.HSC.MEDRECROIFAX@PARALLON.COM</td></tr><tr><td class="td_header_role_name"><span class="td_label">Contact info</span></td><td class="td_header_role_value"> Home Address:<br/>1 Park Plaza<br/>Nashville, TN 37203, US<br/><br/>Tel:  +1-(615)344-9551<br/></td></tr></tbody></table><h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Problems</a></li><li><a href="#id2">Mental Status</a></li><li><a href="#id3">Functional Status</a></li><li><a href="#id4">Allergies and Adverse Reactions</a></li><li><a href="#id5">Medications</a></li><li><a href="#id6">Procedures</a></li><li><a href="#id7">Social History</a></li><li><a href="#id8">Results</a></li><li><a href="#id9">Vital Signs</a></li><li><a href="#id10">Encounters</a></li><li><a href="#id11">Plan of Treatment</a></li><li><a href="#id12">Health Concerns</a></li><li><a href="#id13">Goals</a></li><li><a href="#id14">Assessments</a></li><li><a href="#id15">Medical Equipment</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Problems</a></h3><div><table><colgroup><col width="40%"/><col width="20%"/><col width="40%"/></colgroup><tbody class="xRowGroup"><tr ID="_f743aa6b-24be-491e-856a-ccf0d2f16348"><td><span class="content_span">Gastrointestinal hemorrhage</span><br/></td><td><span class="xLabel xSecondary">Onset: </span><span class="content_span">14-Aug-2021</span><br/><span class="xSecondary">Bierzynski Adam MD</span></td><td/></tr></tbody><tbody class="xRowGroup"><tr ID="_c36d8c42-eba1-4c45-a7af-ed35bab8f50b"><td><span class="content_span">Atrial fibrillation</span><br/></td><td><span class="xLabel xSecondary">Onset: </span><span class="content_span">14-Aug-2021</span><br/><span class="xSecondary">Bierzynski Adam MD</span></td><td/></tr></tbody><tbody class="xRowGroup"><tr ID="_14b53317-af31-49be-993d-d019a740a14a"><td><span class="content_span">Hypertensive disorder</span><br/></td><td><span class="xLabel xSecondary">Onset: </span><span class="content_span">14-Aug-2021</span><br/><span class="xSecondary">Bierzynski Adam MD</span></td><td/></tr></tbody><tbody class="xRowGroup"><tr ID="_7cc32f8e-6fca-4367-9a2c-dde30b109948"><td><span class="content_span">Human immunodeficiency virus infection</span><br/></td><td><span class="xLabel xSecondary">Onset: </span><span class="content_span">14-Aug-2021</span><br/><span class="xSecondary">Bierzynski Adam MD</span></td><td/></tr></tbody><tbody class="xRowGroup"><tr ID="_c9eaf05d-44d7-4a6e-b649-2ce64970a560"><td><span class="content_span">Congestive heart failure</span><br/></td><td><span class="xLabel xSecondary">Onset: </span><span class="content_span">14-Aug-2021</span><br/><span class="xSecondary">Bierzynski Adam MD</span></td><td/></tr></tbody><tbody class="xRowGroup"><tr ID="_de98c3e8-8d36-4adf-b561-72a5f1f8d9f0"><td><span class="content_span">Anemia</span><br/></td><td><span class="xLabel xSecondary">Onset: </span><span class="content_span">12-Aug-2021</span><br/><span class="xSecondary">BRAIS</span></td><td/></tr></tbody><tbody class="xRowGroup"><tr ID="_b82bf91e-c399-446b-9a05-84b14900ab5a"><td><span class="content_span">Asthenia</span><br/></td><td><span class="xLabel xSecondary">Onset: </span><span class="content_span">12-Aug-2021</span><br/><span class="xSecondary">BRAIS</span></td><td/></tr></tbody><tbody class="xRowGroup"><tr ID="_f2679915-087b-40d4-b2a8-7263034d2832"><td><span class="content_span">Cellulitis of chest wall</span><br/></td><td><span class="xLabel xSecondary">Onset: </span><span class="content_span">24-Jun-2017</span><br/><span class="xSecondary">Lugo Ernesto DO</span></td><td/></tr></tbody><tbody class="xRowGroup"><tr ID="_126230b4-3730-447d-90da-2848004d1b90"><td><span class="content_span">Infected pacemaker</span><br/></td><td><span class="xLabel xSecondary">Onset: </span><span class="content_span">24-Jun-2017</span><br/><span class="xSecondary">Lugo Ernesto DO</span></td><td/></tr></tbody><tbody class="xRowGroup"><tr ID="_f01bef85-011b-48aa-bae1-84c9c6ae2650"><td><span class="content_span">Mild coronary artery disease</span><span class="xSecondary"> (I25.10)</span><br/></td><td/><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">Coronary artery disease involving native coronary artery of native heart, angina presence unspecified</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_10c352e2-a2dc-4453-bbdd-db266f13c08d"><td><span class="content_span">Non-rheumatic mitral regurgitation</span><br/></td><td/><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">Non-rheumatic mitral regurgitation</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_0d875fb3-508f-4cb0-85fb-1b8781bec33f"><td><span class="content_span">Heart valve disorder</span><br/></td><td/><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">VHD (valvular heart disease)</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_5167080a-54b1-4401-b83b-eaed4b901479"><td><span class="content_span">Atrial arrhythmia</span><br/></td><td/><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">Atrial dysrhythmia</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_bd9c71b9-a95c-4ff7-8dd3-3af40a753323"><td><span class="content_span">Mechanical complication of heart valve prosthesis</span><br/></td><td/><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">Paravalvular leak of prosthetic heart valve, initial encounter</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_9f06d851-76d3-4aec-9b1e-7a6831db16b9"><td><span class="content_span">Disorder of implantable defibrillator</span><br/></td><td/><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">AICD at end of battery life</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_1b491ee2-9901-4a4c-b8e9-756da0ec21be"><td><span class="content_span">History of aortic valve replacement</span><br/></td><td/><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">S/P AVR (aortic valve replacement)</span></td></tr></tbody></table></div><h3><a name="id2" href="#toc">Mental Status</a></h3><div><table><colgroup><col width="40%"/><col width="20%"/><col width="40%"/></colgroup><tbody class="xRowGroup" ID="_b78ebc2c-592f-492c-bc37-8668a5152eba"><tr><td><content class="xContentWrapping"><span class="xSecondary">Cognitive function finding</span></content></td><td><span class="xSecondary">12-Aug-2021</span></td><td/></tr></tbody></table></div><h3><a name="id3" href="#toc">Functional Status</a></h3><div><table><colgroup><col width="40%"/><col width="20%"/><col width="40%"/></colgroup><tbody class="xRowGroup" ID="_51f926fa-8669-45f2-b100-ad0d5d064bd9"><tr><td><content class="xContentWrapping"><span class="content_span">Functional finding</span></content></td><td><span class="xSecondary">24-Jun-2017</span></td><td/></tr></tbody><tbody class="xRowGroup" ID="_45a18cfd-5ebd-46f1-883f-5acce74ca961"><tr><td><content class="xContentWrapping"><span class="content_span">Functional finding</span></content></td><td><span class="xSecondary">24-Jun-2017</span></td><td/></tr></tbody><tbody class="xRowGroup" ID="_34d4a4bc-a2c8-4fa8-9bef-b26511398b0d"><tr><td><content class="xContentWrapping"><span class="content_span">Functional finding</span></content></td><td><span class="xSecondary">24-Jun-2017</span></td><td/></tr></tbody><tbody class="xRowGroup" ID="_a1985d35-35fd-4b8e-8811-1034c1fd1030"><tr><td><content class="xContentWrapping"><span class="content_span">Functional finding</span></content></td><td><span class="xSecondary">24-Jun-2017</span></td><td/></tr></tbody><tbody class="xRowGroup" ID="_4c1b13e9-fb2d-4b0e-b8a1-7b960aa49a67"><tr><td><content class="xContentWrapping"><span class="content_span">Functional finding</span></content></td><td><span class="xSecondary">24-Jun-2017</span></td><td/></tr></tbody></table></div><h3><a name="id4" href="#toc">Allergies and Adverse Reactions</a></h3><div><table><colgroup><col width="40%"/><col width="20%"/><col width="40%"/></colgroup><tbody><tr ID="_41e8dae4-aa0e-4477-bdfe-01076bb2b03f"><td><span class="content_span">No Known Allergies</span><span class="content_span"> (</span><span class="xSecondary">Allergy</span><span class="content_span">)</span><br/></td><td><span class="xSecondary">Onset: 12-Aug-2021</span></td><td/></tr><tr ID="_7785b23d-4ccf-4e0d-8a3a-09ac2c5de48a"><td><span class="content_span">No Known Drug Allergies</span><span class="content_span"> (</span><span class="xSecondary">Allergy</span><span class="content_span">)</span><br/></td><td><span class="xSecondary">Onset: 26-Apr-2017</span></td><td/></tr></tbody></table></div><h3><a name="id5" href="#toc">Medications</a></h3><div><table><colgroup><col width="40%"/><col width="20%"/><col width="40%"/></colgroup><tbody class="xRowGroup"><tr ID="_83739c5a-e59f-444d-8447-54d726fe2a7d"><td><content class="xContentWrapping"><span class="content_span">2 ML fentaNYL 0.05 MG/ML Injection</span><span class="xLabel">; </span><span class="xSecondary">Provider Administration Instructions:
THIS IS A NARCOTIC ANALGESIC
(C-II CONTROLLED SUBSTANCE)
Common side effects may include respiratory depression,
sedation, Headache, nervousness, sleep disturbances,
dysphoria, euphoria, lightheadedness, alterations of mood</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">Provider Administration Instructions:
THIS IS A NARCOTIC ANALGESIC
(C-II CONTROLLED SUBSTANCE)
Common side effects may include respiratory depression,
sedation, Headache, nervousness, sleep disturbances,
dysphoria, euphoria, lightheadedness, alterations of mood</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_80aead62-3100-4aa1-86e2-9717d8e35679"><td><content class="xContentWrapping"><span class="content_span">ceFAZolin 330 MG/ML Injectable Solution</span><span class="xLabel">; </span><span class="xSecondary">Provider Administration Instructions:
THIS IS A CEPHALOSPORIN ANTIBIOTIC.</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">Provider Administration Instructions:
THIS IS A CEPHALOSPORIN ANTIBIOTIC.</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_6dd1e76b-8f51-46e9-b12a-a336c7fad856"><td><content class="xContentWrapping"><span class="content_span">midazolam 1 MG/ML Injectable Solution</span><span class="xLabel">; </span><span class="xSecondary">Provider Administration Instructions:
**HIGH RISK MEDICATION**
**CAUTION: MAY CAUSE DIZZINESS OR DROWSINESS
********** MAY INCREASE RISK OF FALLS *************</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">Provider Administration Instructions:
**HIGH RISK MEDICATION**
**CAUTION: MAY CAUSE DIZZINESS OR DROWSINESS
********** MAY INCREASE RISK OF FALLS *************</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_04e61e78-bd55-4d73-aabd-d9b2e6f469eb"><td><content class="xContentWrapping"><span class="content_span">calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution</span><span class="xLabel">; </span><span class="xSecondary">Provider Administration Instructions:
**For Use in PACU Dept ONLY**
**THIS IS USED AS AN ELECTROLYTE REPLACEMENT**</span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">Provider Administration Instructions:
**For Use in PACU Dept ONLY**
**THIS IS USED AS AN ELECTROLYTE REPLACEMENT**</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_4a89f13b-f162-4b7f-a392-8096b1b0f596"><td><content class="xContentWrapping"><span class="content_span">acetaminophen 32 MG/ML Oral Solution</span><span class="xLabel">; </span><span class="xSecondary">975 MILLIGRAM  ONCE</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">3 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**
THIS IS AN NON-NARCOTIC ANALGESIC AGENT
Side effects may include rash, nausea/vomiting and elevated
hepatic enzymes.</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_88b4fcbb-d7e0-49ff-8f4d-4a6f17b226b3"><td><content class="xContentWrapping"><span class="content_span">haloperidol 5 MG/ML Injectable Solution</span><span class="xLabel">; </span><span class="xSecondary">5 MILLIGRAM  Q10M PRN</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_df6dcd84-f610-4bcf-8722-888e789d94d3"><td><content class="xContentWrapping"><span class="content_span">1 ML hydrALAZINE hydrochloride 20 MG/ML Injection</span><span class="xLabel">; </span><span class="xSecondary">2 MILLIGRAM  Q10M PRN</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_33e66549-3762-466f-9b3e-01cc2012caef"><td><content class="xContentWrapping"><span class="content_span">1 ML ePHEDrine sulfate 50 MG/ML Injection</span><span class="xLabel">; </span><span class="xSecondary">5 MILLIGRAM  Q5M PRN</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_e85c4799-f2b9-4589-908b-8324690c0e5f"><td><content class="xContentWrapping"><span class="content_span">haloperidol 5 MG/ML Injectable Solution</span><span class="xLabel">; </span><span class="xSecondary">1 MILLIGRAM  ONCE</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_7f200321-b8bb-4c88-921b-34e7ce18cb34"><td><content class="xContentWrapping"><span class="content_span">0.5 ML HYDROmorphone hydrochloride 1 MG/ML Prefilled Syringe</span><span class="xLabel">; </span><span class="xSecondary">0.1 MILLIGRAM  Q5M PRN</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**
*Caution: Each Dilaudid 2mg is equivalent to Morphine 13mg*</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_d6a94597-f3d8-44a2-8661-ea13b4045ca1"><td><content class="xContentWrapping"><span class="content_span">0.5 ML HYDROmorphone hydrochloride 1 MG/ML Prefilled Syringe</span><span class="xLabel">; </span><span class="xSecondary">0.25 MILLIGRAM  Q5M PRN</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**
*Caution: Each Dilaudid 2mg is equivalent to Morphine 13mg*</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_b30b76cc-eba4-4406-952f-8af3d52aeb8c"><td><content class="xContentWrapping"><span class="content_span">0.5 ML HYDROmorphone hydrochloride 1 MG/ML Prefilled Syringe</span><span class="xLabel">; </span><span class="xSecondary">0.5 MILLIGRAM  Q5M PRN</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**
*Caution: Each Dilaudid 2mg is equivalent to Morphine 13mg*</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_12340d48-d527-4caa-9dec-caffa04da5b8"><td><content class="xContentWrapping"><span class="content_span">labetalol hydrochloride 5 MG/ML Injectable Solution</span><span class="xLabel">; </span><span class="xSecondary">5 MILLIGRAM  Q5M PRN</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**
**Multi-Dose vial**
**Inject IV Push doses over 2 minutes**</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_9f03cc40-e1da-4549-90bd-565ca848b228"><td><content class="xContentWrapping"><span class="content_span">1 ML naloxone hydrochloride 0.4 MG/ML Injection</span><span class="xLabel">; </span><span class="xSecondary">0.04 MILLIGRAM  Q3M PRN</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**
**NOTE DOSE: 0.04 MG = 0.1 ML ONLY**</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_c83122c8-1881-4a4f-8b95-cdcb469834d6"><td><content class="xContentWrapping"><span class="content_span">ondansetron 4 MG Disintegrating Oral Tablet [Zofran]</span><span class="xLabel">; </span><span class="xSecondary">4 MILLIGRAM  ASDIR</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**
Place on tongue and allow to dissolve, then swallow.
Therapeutic substitution per PNT</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_ad9d880a-f2c8-4826-a69b-bd907a0687de"><td><content class="xContentWrapping"><span class="content_span">ondansetron 2 MG/ML Injectable Solution [Zofran]</span><span class="xLabel">; </span><span class="xSecondary">4 MILLIGRAM  ASDIR</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_49396c5a-43c2-4fed-a468-2401167c11df"><td><content class="xContentWrapping"><span class="content_span">1 ML meperidine hydrochloride 25 MG/ML Cartridge [Demerol]</span><span class="xLabel">; </span><span class="xSecondary">12.5 MILLIGRAM  ASDIR</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_9015b1dc-262d-4c34-a7dd-54d18a72e643"><td><content class="xContentWrapping"><span class="content_span">midazolam 1 MG/ML Injectable Solution</span><span class="xLabel">; </span><span class="xSecondary">1 MILLIGRAM  Q5M PRN</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">FRALAR</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><span class="xLabel xSecondary"> End: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**For Use in PACU Dept ONLY**</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_5e0e7947-881c-43be-9a79-137fd0577b1b"><td><content class="xContentWrapping"><span class="content_span">lidocaine hydrochloride 10 MG/ML Injectable Solution [Xylocaine]</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_254a127b-5edd-449f-ba00-4fe9430c6e02"><td><content class="xContentWrapping"><span class="content_span">vancomycin 1000 MG Injection</span><span class="xLabel">; </span><span class="xSecondary">Provider Administration Instructions:
Vancomycin 1 GM in 250 ml Sodium Chloride
Infuse over 90 minutes at 166.67 ml/hr
Available from PYXIS</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">Provider Administration Instructions:
Vancomycin 1 GM in 250 ml Sodium Chloride
Infuse over 90 minutes at 166.67 ml/hr
Available from PYXIS</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_a4e0aa3c-d463-4b61-9716-f1b47435a1e5"><td><content class="xContentWrapping"><span class="content_span">lidocaine hydrochloride 10 MG/ML Injectable Solution [Xylocaine]</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_74aeaf2b-6a4e-4b4a-935b-b53e26f60aef"><td><content class="xContentWrapping"><span class="content_span">vancomycin 1000 MG Injection</span><span class="xLabel">; </span><span class="xSecondary">Provider Administration Instructions:
Vancomycin 1 GM in 250 ml Sodium Chloride
Infuse over 90 minutes at 166.67 ml/hr
Available from PYXIS</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">Provider Administration Instructions:
Vancomycin 1 GM in 250 ml Sodium Chloride
Infuse over 90 minutes at 166.67 ml/hr
Available from PYXIS</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_2b7128ed-a16d-43d9-bd05-09db0d0d62a6"><td><content class="xContentWrapping"><span class="content_span">lidocaine hydrochloride 10 MG/ML Injectable Solution [Xylocaine]</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_972f13a8-2926-4846-92ea-9ecbf9635ce1"><td><content class="xContentWrapping"><span class="content_span">2 ML fentaNYL 0.05 MG/ML Injection</span><span class="xLabel">; </span><span class="xSecondary">Provider Administration Instructions:
THIS IS A NARCOTIC ANALGESIC
(C-II CONTROLLED SUBSTANCE)
Common side effects may include respiratory depression,
sedation, Headache, nervousness, sleep disturbances,
dysphoria, euphoria, lightheadedness, alterations of mood</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">Provider Administration Instructions:
THIS IS A NARCOTIC ANALGESIC
(C-II CONTROLLED SUBSTANCE)
Common side effects may include respiratory depression,
sedation, Headache, nervousness, sleep disturbances,
dysphoria, euphoria, lightheadedness, alterations of mood</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_0c195d32-5b34-4b9c-bad3-d700f11e703d"><td><content class="xContentWrapping"><span class="content_span">Etomidate 2 MG/ML Injectable Solution</span><span class="xLabel">; </span><span class="xSecondary">Provider Administration Instructions:
THIS IS AN ANESTHETIC AGENT
(USED FOR RAPID SEQUENCE INTUBATION)
Common side effects may include hyperventilation,
hypoventilation, apnea of short duration (5-90 seconds with
spontaneous recovery), hiccups, laryngospasm, respiratory</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">Provider Administration Instructions:
THIS IS AN ANESTHETIC AGENT
(USED FOR RAPID SEQUENCE INTUBATION)
Common side effects may include hyperventilation,
hypoventilation, apnea of short duration (5-90 seconds with
spontaneous recovery), hiccups, laryngospasm, respiratory</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_27590135-9db0-4baf-ad3a-9eb8c314eedb"><td><content class="xContentWrapping"><span class="content_span">lidocaine hydrochloride 10 MG/ML Injectable Solution [Xylocaine]</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_92daeab8-fff1-4f11-9970-76ee2986480b"><td><content class="xContentWrapping"><span class="content_span">apixaban 5 MG Oral Tablet [Eliquis]</span><span class="xLabel">; </span><span class="xSecondary">5 MILLIGRAM ORAL BID</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">Bierzynski Adam MD</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">15-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_4cad6983-f50d-4631-b88f-4e4d77fcab96"><td><content class="xContentWrapping"><span class="content_span">pantoprazole 40 MG Delayed Release Oral Tablet [Protonix]</span><span class="xLabel">; </span><span class="xSecondary">40 MILLIGRAM ORAL DAILY 0600</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">Bierzynski Adam MD</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">15-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**DELAYED RELEASE PRODUCT - DO NOT CRUSH**
***This drug is for stomach ulcer treatment/prevention****
Most common adverse effects: headache or diarrhea
**FOR PROTONIX USAGE**
Patient must be taking nothing by mouth (for IV Protonix)
Patient must have at least one of the following conditions:
1. Acute non-variceal upper GI bleeding
2. Zollinger-Ellison syndrome (hypersecretory disorders)
3. Severe symptmatic erosive esophagitis or history of
bleeding diathesis</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_b77f962b-5186-4c64-a6a7-1c325267abcc"><td><content class="xContentWrapping"><span class="content_span">lidocaine hydrochloride 10 MG/ML Injectable Solution</span><span class="xLabel">; </span><span class="xSecondary">Provider Administration Instructions:
**HIGH RISK MEDICATION**</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">15-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">Provider Administration Instructions:
**HIGH RISK MEDICATION**</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_4f675c51-44db-4f62-9a55-e42a56f7bb0f"><td><content class="xContentWrapping"><span class="content_span">propofol 10 MG/ML Injectable Suspension</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">15-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_58bc901e-fdaa-4191-af91-eabc0904baa1"><td><content class="xContentWrapping"><span class="content_span">esomeprazole 40 MG Delayed Release Oral Capsule</span><span class="xLabel">; </span><span class="xSecondary">40 MILLIGRAM ORAL DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">15-Aug-2021</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">40 MG PO DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_fdbc1ce3-a304-4f71-afe8-e559d0cc5d51"><td><content class="xContentWrapping"><span class="content_span">simvastatin 20 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">40 MILLIGRAM ORAL DAILY 1800</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">2 </span><br/></content></td><td><span class="content_span">Salerno Peter DO</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">13-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
*****This drug is used to Reduce Cholestrol*****
Most important Medication Side Effect is rhabdomyolysis
which is very rare (less than 1/100,000)
Most common Medcation Side Effects are:Constipation (2.3%),
dyspepsia (1.1%), flatulence (1.9%), and upper respiratory
infection</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_038c8d96-a154-4475-a48a-3d8841c95b46"><td><content class="xContentWrapping"><span class="content_span">100 ML sodium chloride 9 MG/ML Injection</span><span class="xLabel">; </span><span class="xSecondary">11111110
Provider Administration Instructions:
**MUST BE DILUTED  - DO NOT GIVE IV PUSH**
**THIS IS AN INTRAVENOUS IRON SUPPLEMENT**
Common side effects may include injection site reaction
(pain), unspecified pain, asthenia, headache, fatigue,
fever, malaise, rigors, chills, infection, flu-like
syndrome, dizziness, paresthesias, agitation, insomnia,
dyspnea, cough, upper respiratory infection, rhinitis,
hypertension, syncope, tachycardia, bradycardia, pulmonary
edema, dyspepsia, eructation, flatulence, myalgia,</span><br/></content></td><td><span class="content_span">Amin Harshad V MD</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">13-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**MUST BE DILUTED  - DO NOT GIVE IV PUSH**
**THIS IS AN INTRAVENOUS IRON SUPPLEMENT**
Common side effects may include injection site reaction
(pain), unspecified pain, asthenia, headache, fatigue,
fever, malaise, rigors, chills, infection, flu-like
syndrome, dizziness, paresthesias, agitation, insomnia,
dyspnea, cough, upper respiratory infection, rhinitis,
hypertension, syncope, tachycardia, bradycardia, pulmonary
edema, dyspepsia, eructation, flatulence, myalgia,</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_764d9880-c66f-47ea-a9fa-074ae3aae735"><td><content class="xContentWrapping"><span class="content_span">vitamin B12 1 MG/ML Injectable Solution</span><span class="xLabel">; </span><span class="xSecondary">1000 MICROGRAM INTRAMUSCULAR DAILY</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">Amin Harshad V MD</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">13-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
THIS IS VITAMIN B12 (WATER SOLUBLE VITAMIN)
Common side effects following IM injection may include
anxiety, mild transient diarrhea, ataxia, nervousness,
pruritus, transitory exanthema, and a feeling of swelling of
the entire body.</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_42928791-b687-4558-afa7-43a074d1e750"><td><content class="xContentWrapping"><span class="content_span">apixaban 5 MG Oral Tablet [Eliquis]</span><span class="xLabel">; </span><span class="xSecondary">5 MILLIGRAM ORAL Q12HR</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">Salerno Peter DO</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">13-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_d82990e8-506b-4f27-9238-0f5a628fbc5e"><td><content class="xContentWrapping"><span class="content_span">losartan potassium 50 MG Oral Tablet [Cozaar]</span><span class="xLabel">; </span><span class="xSecondary">50 MILLIGRAM ORAL BID</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">Salerno Peter DO</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">13-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
Side effects: diarrhea, heartburn and possible swelling</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_3e4081b8-a916-4941-80dc-7e7f5ea9776a"><td><content class="xContentWrapping"><span class="content_span">metoprolol tartrate 50 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">50 MILLIGRAM ORAL Q12HR</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">Salerno Peter DO</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">13-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
**THIS DRUG IS A BETA BLOCKER**
**Side effects may include bradycardia, diarrhea,
nausea/vomiting**</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_050f1e01-3662-4504-822c-21306a4c60e8"><td><content class="xContentWrapping"><span class="content_span">PATIENT'S OWN MEDICATION_POM</span><span class="xLabel">; </span><span class="xSecondary">11111110
Provider Administration Instructions:
BIKTARVY   50-200-25 TABLETS
TAKE 1 TABLET BY MOUTH DAILY
BIKTARVY   50-200-25 TABLETS
TAKE 1 TABLET BY MOUTH DAILY</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">0 </span><br/></content></td><td><span class="content_span">Salerno Peter DO</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">13-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
BIKTARVY   50-200-25 TABLETS
TAKE 1 TABLET BY MOUTH DAILY
BIKTARVY   50-200-25 TABLETS
TAKE 1 TABLET BY MOUTH DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_256c1bb2-6808-4a01-82c3-65be5371b242"><td><content class="xContentWrapping"><span class="content_span">aspirin 81 MG Delayed Release Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">81 MILLIGRAM ORAL C BK</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">Salerno Peter DO</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">13-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110
Provider Administration Instructions:
THIS IS AN ANALGESIC (NONSTEROIDAL ANTI-INFLAMMATORY AGENT)
Common side effects may include bleeding, nausea/vomiting,
abdominal pain, heartburn, edema and tinnitus.</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_3ab89e4f-5165-423e-be12-c9cabf165aa2"><td><content class="xContentWrapping"><span class="content_span">apixaban 5 MG Oral Tablet [Eliquis]</span><span class="xLabel">; </span><span class="xSecondary">5 MILLIGRAM ORAL Q2HR</span><br/><span class="xLabel"> Quantity: </span><span class="content_span">1 </span><br/></content></td><td><span class="content_span">Salerno Peter DO</span></td><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">13-Aug-2021</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">11111110</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_3d24bbdd-8f4b-4e6a-9333-542bc1406234"><td><content class="xContentWrapping"><span class="content_span">metoprolol tartrate 50 MG Oral Tablet [Lopressor]</span><span class="xLabel">; </span><span class="xSecondary">50 MILLIGRAM ORAL Q12H</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Aug-2021</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">50 MG PO Q12H</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_4aaad8ff-df32-4554-90b6-74702bd6e42b"><td><content class="xContentWrapping"><span class="content_span">apixaban 5 MG Oral Tablet [Eliquis]</span><span class="xLabel">; </span><span class="xSecondary">5 MILLIGRAM ORAL Q12HR</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Aug-2021</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">5 MG PO Q12HR</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_c1a79089-b0d7-4cd3-9043-677e0e808170"><td><content class="xContentWrapping"><span class="content_span">BIKTARVY</span><span class="xLabel">; </span><span class="xSecondary">1 EACH ORAL DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">12-Aug-2021</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">1 EACH PO DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_83cc6f12-7c87-4ae9-bfa8-e1615300b4af"><td><content class="xContentWrapping"><span class="content_span">ciprofloxacin 500 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">500 MILLIGRAM ORAL BID</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">27-Jun-2017</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">500 MG PO BID</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_bce8b9bc-4be7-482c-9add-d1348cf6445f"><td><content class="xContentWrapping"><span class="content_span">0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe</span><span class="xLabel">; </span><span class="xSecondary">80 MILLIGRAM SUBCUTANEOUS DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">13-Jun-2017</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">80 MG SUBQ DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_1bbeef27-6440-41cb-8225-2c112c30ec88"><td><content class="xContentWrapping"><span class="content_span">omega-3 acid ethyl esters (USP) 1000 MG Oral Capsule</span><span class="xLabel">; </span><span class="xSecondary">1 CAPSULE ORAL DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">8-Jun-2017</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">1 CAP PO DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_e93b7b96-0f02-4cb6-99f2-dde50012a9f5"><td><content class="xContentWrapping"><span class="content_span">losartan potassium 50 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">50 MILLIGRAM PO BID</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">27-Apr-2017</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">50 MG PO BID</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_03be10bf-e679-49fc-8e4b-5ac0b2628bf7"><td><content class="xContentWrapping"><span class="content_span">TOPROL XL 25MG TAB</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">27-Apr-2017</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_e8b60318-a5a2-435a-9a77-4f435ef6cbb2"><td><content class="xContentWrapping"><span class="content_span">aspirin 81 MG Delayed Release Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">81 MILLIGRAM PO DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">27-Apr-2017</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">81 MG PO DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_9607e86e-dfc3-4c1a-9c14-9d5e2e4ab563"><td><content class="xContentWrapping"><span class="content_span">ATRIPLA 600/200/300 MG TAB</span><span class="xLabel">; </span><span class="xSecondary">1 TABLET PO DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">27-Apr-2017</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">1 TAB PO DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_086bbdb8-ce11-40ae-8006-18dfc27e8d81"><td><content class="xContentWrapping"><span class="content_span">0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe</span><span class="xLabel">; </span><span class="xSecondary">80 MILLIGRAM SUBCUTANEOUS DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">27-Apr-2017</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">80 MG SUBQ DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_747f5cf3-7425-4734-8cfe-99886530afbd"><td><content class="xContentWrapping"><span class="content_span">warfarin sodium 5 MG Oral Tablet [Coumadin]</span><span class="xLabel">; </span><span class="xSecondary">5 MILLIGRAM PO DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">27-Apr-2017</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">5 MG PO DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_f7def9b2-cf73-4060-ade4-ba7b74e16753"><td><content class="xContentWrapping"><span class="content_span">warfarin sodium 10 MG Oral Tablet [Coumadin]</span><span class="xLabel">; </span><span class="xSecondary">10 MILLIGRAM PO DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">27-Apr-2017</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">10 MG PO DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_7d4ad102-a854-434b-bd50-51cf890caaff"><td><content class="xContentWrapping"><span class="content_span">simvastatin 40 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">40 MILLIGRAM PO BEDTIME</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">27-Apr-2017</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">40 MG PO BEDTIME</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_85a7bd92-c92a-40d1-9b27-dcd6dc75c772"><td><content class="xContentWrapping"><span class="content_span">aspirin 81 MG Delayed Release Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">81 MILLIGRAM ORAL DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">17-Jan-2017</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">81 MG PO DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_14939d47-545f-4d79-b4c2-eb4b62e26217"><td><content class="xContentWrapping"><span class="content_span">PERCOCET 10/325 MG</span><span class="xLabel">; </span><span class="xSecondary">1 TABLET ORAL Q4H PRN</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">10-Apr-2013</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">1 TAB PO Q4H PRN</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_c2d20ddb-a6b1-4b0d-98c0-925dbc2f07fe"><td><content class="xContentWrapping"><span class="content_span">ATRIPLA</span><span class="xLabel">; </span><span class="xSecondary">600 MG PO DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">10-Apr-2013</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_58451922-8877-4c60-ae07-7646dd9a84d8"><td><content class="xContentWrapping"><span class="content_span">warfarin sodium 1 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">5 MG PO DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">10-Apr-2013</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_d2438579-be6d-4864-8f59-312d9925792b"><td><content class="xContentWrapping"><span class="content_span">ATRIPLA</span><span class="xLabel">; </span><span class="xSecondary">600 MILLIGRAM ORAL DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">10-Apr-2013</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">600 MG PO DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_5240b1f5-5efb-47f9-b314-16665eaf5c6c"><td><content class="xContentWrapping"><span class="content_span">warfarin sodium 1 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">5 MILLIGRAM ORAL DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">10-Apr-2013</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">5 MG PO DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_ad089364-d3c8-4ebc-bccb-cc745485db5d"><td><content class="xContentWrapping"><span class="content_span">LOPRESSOR</span><span class="xLabel">; </span><span class="xSecondary">25 MILLIGRAM ORAL BID</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">10-Apr-2013</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">25 MG PO BID</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_cc80e6aa-ae50-41b0-b45f-763d8bd426f7"><td><content class="xContentWrapping"><span class="content_span">simvastatin 40 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">40 MG PO DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">18-Dec-2012</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_c7753408-24c9-425d-be66-4cbff7486516"><td><content class="xContentWrapping"><span class="content_span">24 HR metoprolol succinate 25 MG Extended Release Oral Tablet [Toprol]</span><span class="xLabel">; </span><span class="xSecondary">25 MG PO DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">18-Dec-2012</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_332d0c90-ff0c-49f7-bb08-eda15875b079"><td><content class="xContentWrapping"><span class="content_span">losartan potassium 50 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">50 MG PO BID</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">18-Dec-2012</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_34805b68-715b-419f-9cb1-b3a2a401b31c"><td><content class="xContentWrapping"><span class="content_span">COUMADIN</span><span class="xLabel">; </span><span class="xSecondary">10 MG PO DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">18-Dec-2012</span><br/><span class="xLabel">Status: </span><span class="content_span">Discontinued</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_0b5270bb-e2b7-425c-8830-425d32c5eab2"><td><content class="xContentWrapping"><span class="content_span">losartan potassium 50 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">50 MILLIGRAM ORAL BID</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">18-Dec-2012</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">50 MG PO BID</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_4af932f8-f48b-4a36-a346-bb722b390984"><td><content class="xContentWrapping"><span class="content_span">simvastatin 40 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">40 MILLIGRAM ORAL DAILY</span><br/></content></td><td/><td><span class="xLabel xSecondary">Start: </span><span class="xSecondary">18-Dec-2012</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">40 MG PO DAILY</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_2f85d41f-2778-407f-9703-3172c3c56400"><td><content class="xContentWrapping"><span class="content_span">Losartan Potassium 50 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">50 MG Orally bid, 1 tablet</span><br/></content></td><td><span class="content_span">BACHAR DAHMAN</span></td><td><span class="xLabel">Comments: </span><span class="xSecondary">50 MG Orally bid, 1 tablet</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_6e8a05df-aa6d-4f4a-a12f-bc28fa48ccf4"><td><content class="xContentWrapping"><span class="content_span">Warfarin Sodium 10 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">10 MG Orally Once a day, 1 tablet</span><br/></content></td><td><span class="content_span">BACHAR DAHMAN</span></td><td><span class="xLabel">Status: </span><span class="content_span">Inactive</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">10 MG Orally Once a day, 1 tablet</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_5066cf85-810e-4a3a-962c-6b6aae873e24"><td><content class="xContentWrapping"><span class="content_span">Aspirin 81 MG Delayed Release Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">81 MG Orally Once a day, 1 tablet</span><br/></content></td><td><span class="content_span">BACHAR DAHMAN</span></td><td><span class="xLabel">Status: </span><span class="content_span">Inactive</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">81 MG Orally Once a day, 1 tablet</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_148498fa-0010-4599-8b15-4ea7d2516a65"><td><content class="xContentWrapping"><span class="content_span">24 HR metoprolol succinate 50 MG Extended Release Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">50 MG Orally bid, 1 tablet</span><br/></content></td><td><span class="content_span">BACHAR DAHMAN</span></td><td><span class="xLabel">Comments: </span><span class="xSecondary">50 MG Orally bid, 1 tablet</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_56df02ba-fb88-4f7e-b650-dd700c5bdfc2"><td><content class="xContentWrapping"><span class="content_span">Acetaminophen 325 MG / HYDROcodone Bitartrate 5 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">5-325 MG Orally every 6 hrs, 1 tablet as needed</span><br/></content></td><td><span class="content_span">BACHAR DAHMAN</span></td><td><span class="xLabel">Comments: </span><span class="xSecondary">5-325 MG Orally every 6 hrs, 1 tablet as needed</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_1259f38b-b218-41d6-b51c-962710c5475c"><td><content class="xContentWrapping"><span class="content_span">Fish Oil</span><span class="xLabel">; </span><span class="xSecondary">1000 MG Orally Once a day, 1 capsule</span><br/></content></td><td><span class="content_span">BACHAR DAHMAN</span></td><td><span class="xLabel">Status: </span><span class="content_span">Inactive</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">1000 MG Orally Once a day, 1 capsule</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_7b070005-910c-4e80-a9b3-040f587b7544"><td><content class="xContentWrapping"><span class="content_span">Krill Oil</span><span class="xLabel">; </span><span class="xSecondary">1000 MG Orally , as directed</span><br/></content></td><td><span class="content_span">BACHAR DAHMAN</span></td><td><span class="xLabel">Comments: </span><span class="xSecondary">1000 MG Orally , as directed</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_b98a1d18-902d-4b73-9b8f-36f4af17d7a3"><td><content class="xContentWrapping"><span class="content_span">efavirenz 600 MG / emtricitabine 200 MG / Tenofovir disoproxil fumarate 300 MG Oral Tablet [Atripla]</span><span class="xLabel">; </span><span class="xSecondary">600-200-300 MG Orally Once a day, 1 tablet on an empty stomach</span><br/></content></td><td><span class="content_span">BACHAR DAHMAN</span></td><td><span class="xLabel">Status: </span><span class="content_span">Inactive</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">600-200-300 MG Orally Once a day, 1 tablet on an empty stomach</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_dd2213cb-eabb-418c-a366-2c4dbe016de9"><td><content class="xContentWrapping"><span class="content_span">Simvastatin</span><span class="xLabel">; </span><span class="xSecondary">40 MG Orally Once a day, 1 tablet in the evening</span><br/></content></td><td><span class="content_span">BACHAR DAHMAN</span></td><td><span class="xLabel">Comments: </span><span class="xSecondary">40 MG Orally Once a day, 1 tablet in the evening</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_4d702bd4-bdc2-4af8-95ff-25ab99720058"><td><content class="xContentWrapping"><span class="content_span">Ultra Multi Formula/Iron</span><span class="xLabel">; </span><span class="xSecondary">- Orally ,</span><br/></content></td><td><span class="content_span">BACHAR DAHMAN</span></td><td><span class="xLabel">Comments: </span><span class="xSecondary">- Orally ,</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_b29dc6da-f20f-4345-8c44-1071a0db5242"><td><content class="xContentWrapping"><span class="content_span">Vitamin C</span><span class="xLabel">; </span><span class="xSecondary">1000 MG Orally Once a day, 1 tablet</span><br/></content></td><td><span class="content_span">BACHAR DAHMAN</span></td><td><span class="xLabel">Comments: </span><span class="xSecondary">1000 MG Orally Once a day, 1 tablet</span></td></tr></tbody><tbody class="xRowGroup"><tr ID="_12d6dd61-3772-4556-ba6e-5a9f85cb02d7"><td><content class="xContentWrapping"><span class="content_span">Ciprofloxacin 500 MG Oral Tablet</span><span class="xLabel">; </span><span class="xSecondary">500 MG Orally Twice a day, 1 tablet</span><br/></content></td><td><span class="content_span">BACHAR DAHMAN</span></td><td><span class="xLabel">Status: </span><span class="content_span">Inactive</span><br/><span class="xLabel">Comments: </span><span class="xSecondary">500 MG Orally Twice a day, 1 tablet</span></td></tr></tbody></table></div><h3><a name="id6" href="#toc">Procedures</a></h3><div><table><colgroup><col width="40%"/><col width="20%"/><col width="40%"/></colgroup><tbody class="xRowGroup"><tr ID="_5ca33880-22a7-4a9f-98c6-5d090179ff59"><td><span class="content_span">RMVL &amp; RPLCMT DFB GEN MLT LD</span></td><td><span class="xLabel xSecondary">Date: </span><span class="xSecondary">12-Jul-2024</span><br/></td><td/></tr></tbody></table><table><colgroup><col width="40%"/><col width="20%"/><col width="40%"/></colgroup><tbody class="xRowGroup"><tr ID="_b66ae267-022f-455f-b4b3-75130de88f7a"><td colspan="2"><p>CHEST AP ONLY PORTABLE</p><span class="xLabel">Result: </span><span class="content_span">
  WESTSIDE DIAGNOSTIC IMAGING       Name: MANNELLINO,DOMINICK           
  8201 W. BROWARD BLVD              Phys: Satija,Sameer  MD             
  PLANTATION, FL  33324             DOB:  10/03/1946   Age: 77      Sex: M
                                    Acct: W00021284755 Loc: W.CCL     
  PHONE #: 954-476-3918             Exam Date: 07/12/2024 Status: REG SDC 
    FAX #: 954-476-3983             Unit: W000313546     PACS: BW230887   
                                Exam Completed: 07/12/24   @ 0913




  EXAMS:                                                              
  003354821 CHEST AP ONLY PORTABLE                                    

       HISTORY:                                                                
     Dyspnea                                                                 
     Technique: Two radiographic views of the chest                          
     Comparison:08/12/2021                                                   

       IMPRESSION:                                                             
       Cardiac silhouette is stable.  Low lung volumes with vascular  
       crowding.  Left-sided pacemaker stable.  No pneumothorax.  Osseous  
       structures are stable  
       Workstation ID: MERCCDID05                                              



** Electronically Signed by Hilda Tejero MD on 07/12/2024 at 0932 **  
                    Reported and signed by: Hilda Tejero, MD    






















CC: Sameer Satija MD                                                  

Dictated Date/Time: 07/12/2024 (0932)
Technologist: Christian Borja,RT, (R); Fazal Imam,RT, (R)            
Transcribed Date/Time: 07/12/2024 (0932)
Transcriptionist: UMR:RAD                            
Electronic Signature Date/Time: 07/12/2024 (0932)
Orig Print D/T: S: 07/12/2024 (0936)                        

PAGE  1                       Signed Report</span></td><td><span class="xLabel xSecondary"> Date: </span><span class="xSecondary">12-Jul-2024</span><br/><span class="xLabel xSecondary"> Status: </span><span class="xSecondary">Completed</span><br/></td></tr></tbody></table></div><h3><a name="id7" href="#toc">Social History</a></h3><div><table><span style="font-weight:bold; ">Smoking Status</span><colgroup><col width="40%"/><col width="20%"/><col width="40%"/></colgroup><tbody class="xRowGroup"><tr ID="_ac9ddb66-244b-40aa-a2f0-3de3cc7a6c11"><td><span class="xSecondary">Never smoked tobacco</span></td><td><span class="xSecondary">Recorded: 12-Aug-2021</span></td><td/></tr></tbody><tbody class="xRowGroup"><tr ID="_f4beaa2c-0537-48b7-9354-4d945686d662"><td><span class="xSecondary">Never smoked tobacco</span></td><td><span class="xSecondary">Recorded: 24-Jun-2017</span></td><td/></tr></tbody></table></div><h3><a name="id8" href="#toc">Results</a></h3><div><table><colgroup><col width="20%"/><col width="40%"/><col width="40%"/></colgroup><tbody class="xRowGroup"><tr><td><span class="xSecondary">CBC WITH DIFFERENTIAL</span></td><td><span class="xLabel">Ordered On: </span><span class="content_span">12-Jul-2024</span></td><td/></tr><tr ID="_451edee9-c3ed-46bb-aaf4-0ec716bc1c3a"><td><span class="xSecondary xContentWrapping">12-Jul-2024 07:53</span></td><td><span class="xSecondary">Basophil Absolute #</span><span class="xSecondary"> 0.01</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">0.01</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> - </span><span class="xSecondary">0.08</span><span class="xSecondary"> 10*3/uL</span><br/></content></td></tr><tr ID="_2092dba5-4745-47dc-b765-d9f4939670dc"><td/><td><span class="xSecondary">Basophil</span><span class="xSecondary"> 0.3</span><span class="xSecondary"> %</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">0.2</span><span class="xSecondary"> %</span><span class="xSecondary"> - </span><span class="xSecondary">1.2</span><span class="xSecondary"> %</span><br/></content></td></tr><tr ID="_9676b485-f8ea-47f0-9510-e4f3672f2730"><td/><td><span class="xSecondary">Eosinophil</span><span class="xSecondary"> 2.3</span><span class="xSecondary"> %</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">0.8</span><span class="xSecondary"> %</span><span class="xSecondary"> - </span><span class="xSecondary">7</span><span class="xSecondary"> %</span><br/></content></td></tr><tr ID="_11716c68-9e0b-47e1-a7cd-4c831f44ef6d"><td/><td><span class="xSecondary">Lymphocyte</span><span class="xSecondary"> 17.8</span><span class="xSecondary"> %</span><span class="xSecondary"> (Low)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">21.8</span><span class="xSecondary"> %</span><span class="xSecondary"> - </span><span class="xSecondary">53.1</span><span class="xSecondary"> %</span><br/></content></td></tr><tr ID="_8ecd2e33-60e4-4a53-b5d4-d551a56f1ef4"><td/><td><span class="xSecondary">Monocyte</span><span class="xSecondary"> 10.3</span><span class="xSecondary"> %</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">5.3</span><span class="xSecondary"> %</span><span class="xSecondary"> - </span><span class="xSecondary">12.2</span><span class="xSecondary"> %</span><br/></content></td></tr><tr ID="_a2d285d1-6b50-475b-bb72-e6b65ff86348"><td/><td><span class="xSecondary">Nucleated RBC #</span><span class="xSecondary"> 0.00</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">0</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> - </span><span class="xSecondary">0.18</span><span class="xSecondary"> 10*3/uL</span><br/></content></td></tr><tr ID="_88f4cd0a-8bd8-4e66-89a7-d21482129eae"><td/><td><span class="xSecondary">Nucleated RBC %</span><span class="xSecondary"> 0.0</span><span class="xSecondary"> %</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">0</span><span class="xSecondary"> %</span><span class="xSecondary"> - </span><span class="xSecondary">0.2</span><span class="xSecondary"> %</span><br/></content></td></tr><tr ID="_80f66fe5-18d3-460a-a999-cb5809bc20f1"><td/><td><span class="xSecondary">Eosinophil Absolute #</span><span class="xSecondary"> 0.09</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">0.04</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> - </span><span class="xSecondary">0.54</span><span class="xSecondary"> 10*3/uL</span><br/></content></td></tr><tr ID="_5576caab-f023-4e00-a18d-d6e88488921f"><td/><td><span class="xSecondary">Segmented Neutrophil</span><span class="xSecondary"> 68.8</span><span class="xSecondary"> %</span><span class="xSecondary"> (High)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">34</span><span class="xSecondary"> %</span><span class="xSecondary"> - </span><span class="xSecondary">67.9</span><span class="xSecondary"> %</span><br/></content></td></tr><tr ID="_69421b94-36dc-4a94-a31a-0bbe9ec21645"><td/><td><span class="xSecondary">Hematocrit</span><span class="xSecondary"> 37.8</span><span class="xSecondary"> %</span><span class="xSecondary"> (Low)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">40.1</span><span class="xSecondary"> %</span><span class="xSecondary"> - </span><span class="xSecondary">51</span><span class="xSecondary"> %</span><br/></content></td></tr><tr ID="_4ada53fd-370b-4bf0-91de-b86f22cf707d"><td/><td><span class="xSecondary">Hemoglobin</span><span class="xSecondary"> 12.9</span><span class="xSecondary"> g/dL</span><span class="xSecondary"> (Low)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">13.7</span><span class="xSecondary"> g/dL</span><span class="xSecondary"> - </span><span class="xSecondary">17.5</span><span class="xSecondary"> g/dL</span><br/></content></td></tr><tr ID="_6e6ca649-53e8-43df-b734-55487c868e70"><td/><td><span class="xSecondary">Immature Granulocytes #</span><span class="xSecondary"> 0.02</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">0</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> - </span><span class="xSecondary">0.03</span><span class="xSecondary"> 10*3/uL</span><br/></content></td></tr><tr ID="_cd3703b5-9960-44dc-aa7e-6dd3e068a5ca"><td/><td><span class="xSecondary">Immature Granulocytes %</span><span class="xSecondary"> 0.5</span><span class="xSecondary"> %</span><span class="xSecondary"> (High)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">0</span><span class="xSecondary"> %</span><span class="xSecondary"> - </span><span class="xSecondary">0.4</span><span class="xSecondary"> %</span><br/></content></td></tr><tr ID="_77b5a63e-6e9d-4074-a72c-ca43ddf8e4c7"><td/><td><span class="xSecondary">Lymphocyte Absolute #</span><span class="xSecondary"> 0.71</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> (Low)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">1.32</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> - </span><span class="xSecondary">3.57</span><span class="xSecondary"> 10*3/uL</span><br/></content></td></tr><tr ID="_0c379113-2e3b-4e8e-918d-1e68b1f57aec"><td/><td><span class="xSecondary">Manual Differential?</span><span class="xSecondary"> NO</span></td><td/></tr><tr ID="_aa9d347a-bebe-4314-8ee2-19ffed1ba45f"><td/><td><span class="xSecondary">MCH</span><span class="xSecondary"> 34.3</span><span class="xSecondary"> pg</span><span class="xSecondary"> (High)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">25.7</span><span class="xSecondary"> pg</span><span class="xSecondary"> - </span><span class="xSecondary">32.2</span><span class="xSecondary"> pg</span><br/></content></td></tr><tr ID="_c059abed-2006-491e-a9bc-b233e7c29a79"><td/><td><span class="xSecondary">MCHC</span><span class="xSecondary"> 34.1</span><span class="xSecondary"> g/dL</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">32.3</span><span class="xSecondary"> g/dL</span><span class="xSecondary"> - </span><span class="xSecondary">36.5</span><span class="xSecondary"> g/dL</span><br/></content></td></tr><tr ID="_485ea453-fb3b-413c-8a70-e2557d123181"><td/><td><span class="xSecondary">MCV</span><span class="xSecondary"> 100.5</span><span class="xSecondary"> fL</span><span class="xSecondary"> (High)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">79</span><span class="xSecondary"> fL</span><span class="xSecondary"> - </span><span class="xSecondary">92.2</span><span class="xSecondary"> fL</span><br/></content></td></tr><tr ID="_7bb7e3e9-8718-47ed-909b-c2d0c50d50a4"><td/><td><span class="xSecondary">Monocyte Absolute #</span><span class="xSecondary"> 0.41</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">0.3</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> - </span><span class="xSecondary">0.82</span><span class="xSecondary"> 10*3/uL</span><br/></content></td></tr><tr ID="_1d63a0e6-8082-41f2-afd1-7b259344fa86"><td/><td><span class="xSecondary">MEAN PLATLET VOL</span><span class="xSecondary"> 9.3</span><span class="xSecondary"> fL</span><span class="xSecondary"> (Low)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">9.4</span><span class="xSecondary"> fL</span><span class="xSecondary"> - </span><span class="xSecondary">12.4</span><span class="xSecondary"> fL</span><br/></content></td></tr><tr ID="_e0aac469-0a76-43f1-98e0-2b3c65732fef"><td/><td><span class="xSecondary">Neutrophil Absolute #</span><span class="xSecondary"> 2.74</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">1.78</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> - </span><span class="xSecondary">5.38</span><span class="xSecondary"> 10*3/uL</span><br/></content></td></tr><tr ID="_708a6ff1-924f-4200-88cd-08c99033af30"><td/><td><span class="xSecondary">PLATELET</span><span class="xSecondary"> 99</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> (Low)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">150</span><span class="xSecondary"> 10*3/uL</span><span class="xSecondary"> - </span><span class="xSecondary">400</span><span class="xSecondary"> 10*3/uL</span><br/></content></td></tr><tr ID="_585e0901-f81a-4b81-ac51-a9cf1bff86de"><td/><td><span class="xSecondary">RBC</span><span class="xSecondary"> 3.76</span><span class="xSecondary"> 10*6/uL</span><span class="xSecondary"> (Low)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">4.63</span><span class="xSecondary"> 10*6/uL</span><span class="xSecondary"> - </span><span class="xSecondary">6.08</span><span class="xSecondary"> 10*6/uL</span><br/></content></td></tr><tr ID="_bb706353-f801-4f00-bc36-1fb8b26d4c79"><td/><td><span class="xSecondary">RDW</span><span class="xSecondary"> 13.1</span><span class="xSecondary"> %</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">11.6</span><span class="xSecondary"> %</span><span class="xSecondary"> - </span><span class="xSecondary">14.4</span><span class="xSecondary"> %</span><br/></content></td></tr><tr ID="_8cf22efa-0876-4f4d-bb3f-483eab669ada"><td/><td><span class="xSecondary">WBC</span><span class="xSecondary"> 4.0</span><span class="xSecondary"> {10_3/u}</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">4</span><span class="xSecondary"> {10_3/u}</span><span class="xSecondary"> - </span><span class="xSecondary">10.5</span><span class="xSecondary"> {10_3/u}</span><br/></content></td></tr></tbody><tbody class="xRowGroup"><tr><td><span class="xSecondary">BASIC METABOLIC PANEL</span></td><td><span class="xLabel">Ordered On: </span><span class="content_span">12-Jul-2024</span></td><td/></tr><tr ID="_007a1331-7eb0-462e-8e20-423aa2bd1951"><td><span class="xSecondary xContentWrapping">12-Jul-2024 08:03</span></td><td><span class="xSecondary">Urea Nitrogen Blood (BUN)</span><span class="xSecondary"> 19</span><span class="xSecondary"> mg/dL</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">6</span><span class="xSecondary"> mg/dL</span><span class="xSecondary"> - </span><span class="xSecondary">22</span><span class="xSecondary"> mg/dL</span><br/></content></td></tr><tr ID="_10726466-fd25-4891-b16f-7ed6b51f43cc"><td/><td><span class="xSecondary">Calcium (Serum)</span><span class="xSecondary"> 9.2</span><span class="xSecondary"> mg/dL</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">8.4</span><span class="xSecondary"> mg/dL</span><span class="xSecondary"> - </span><span class="xSecondary">10.2</span><span class="xSecondary"> mg/dL</span><br/></content></td></tr><tr ID="_cfbb510b-5dc7-43cb-b063-8c4a3d091e5a"><td/><td><span class="xSecondary">Chloride (Serum)</span><span class="xSecondary"> 109</span><span class="xSecondary"> mmol/L</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">95</span><span class="xSecondary"> mmol/L</span><span class="xSecondary"> - </span><span class="xSecondary">110</span><span class="xSecondary"> mmol/L</span><br/></content></td></tr><tr ID="_07c9e065-533b-41de-bda9-46fd230fc10a"><td/><td><span class="xSecondary">Carbon Dioxide (CO2)</span><span class="xSecondary"> 27</span><span class="xSecondary"> mmol/L</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">19</span><span class="xSecondary"> mmol/L</span><span class="xSecondary"> - </span><span class="xSecondary">34</span><span class="xSecondary"> mmol/L</span><br/></content></td></tr><tr ID="_bd4e6b95-0a4e-4e31-be39-373fcc05fa37"><td/><td><span class="xSecondary">Creatinine (Serum)</span><span class="xSecondary"> 0.95</span><span class="xSecondary"> mg/dL</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">0.43</span><span class="xSecondary"> mg/dL</span><span class="xSecondary"> - </span><span class="xSecondary">1.13</span><span class="xSecondary"> mg/dL</span><br/></content><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">The eGFR is calculated using the 2021 CKD-EPI Cr equation,
which includes serum Cr, age, and sex but does not include a
race coefficient. The National Kidney Foundation recommends
this formula for calculating eGFR in adults. GFR will not
calculate if sex is unknown, patient age is &lt;18 years or if
serum Creatinine is &lt;0.20 mg/dL or non-numerical.</span></td></tr><tr ID="_b89d5cf4-e96d-4176-99f6-82460ac95101"><td/><td><span class="xSecondary">eGFR</span><span class="xSecondary"> 82</span><span class="xSecondary"> (Low)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary"> &gt;/=90</span><br/></content><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">Ref range: &gt;/= 90 mL/min/1.73 m2</span></td></tr><tr ID="_54470114-4eee-42b2-9b63-2759074059c1"><td/><td><span class="xSecondary">Glucose</span><span class="xSecondary"> 120</span><span class="xSecondary"> mg/dL</span><span class="xSecondary"> (High)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">70</span><span class="xSecondary"> mg/dL</span><span class="xSecondary"> - </span><span class="xSecondary">110</span><span class="xSecondary"> mg/dL</span><br/></content></td></tr><tr ID="_c41a1174-6a24-4d53-8ed4-b4c9de15bdff"><td/><td><span class="xSecondary">Potassium (Serum)</span><span class="xSecondary"> 4.5</span><span class="xSecondary"> mmol/L</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">3.5</span><span class="xSecondary"> mmol/L</span><span class="xSecondary"> - </span><span class="xSecondary">5.2</span><span class="xSecondary"> mmol/L</span><br/></content></td></tr><tr ID="_51d7a3e1-c9d1-4ff9-bc5e-2674dc3db35e"><td/><td><span class="xSecondary">Sodium (Serum)</span><span class="xSecondary"> 140</span><span class="xSecondary"> mmol/L</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">135</span><span class="xSecondary"> mmol/L</span><span class="xSecondary"> - </span><span class="xSecondary">145</span><span class="xSecondary"> mmol/L</span><br/></content></td></tr></tbody><tbody class="xRowGroup"><tr><td><span class="xSecondary">Prothrombin Time (PT)</span></td><td><span class="xLabel">Ordered On: </span><span class="content_span">12-Jul-2024</span></td><td/></tr><tr ID="_da5b621e-3d4f-4871-8866-c56d0fef4ed4"><td><span class="xSecondary xContentWrapping">12-Jul-2024 08:04</span></td><td><span class="xSecondary">PT</span><span class="xSecondary"> 12.5</span><span class="xSecondary"> s</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">10</span><span class="xSecondary"> s</span><span class="xSecondary"> - </span><span class="xSecondary">12.8</span><span class="xSecondary"> s</span><br/></content></td></tr><tr ID="_b2bf7285-070b-40ed-ac0f-a44e8e060419"><td/><td><span class="xSecondary">Prothrombin Time INR</span><span class="xSecondary"> 1.1</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">0.8</span><span class="xSecondary"> - </span><span class="xSecondary">1.1</span><br/></content><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">Use INR for clinical decision making
Recommended Therapeutic Range:
INDICATION                              TARGETED INR RANGE
Prevention and treatment of VTE           2.0-3.0
Atrial Fibrillation                       2.0-3.0
Acute myocardial infarction               2.0-3.0
Valvular heart disease                    2.0-3.0
Prosthetic tissue heart valves            2.5-3.5
Recurrent Thromboembolism                 2.5-3.5

Targeted INR range of 2-3 is appropriate for patients who
have a mechanical bileaflet in the aortic position, normal
cardiac chamber size, and no other risk factors for stroke.

Co-administration of argatroban and warfarin produces a
combined effect on INR.  Consult pharmacist or physician to
determine if warfarin dose should be held when INR is
elevated and patient is receiving argatroban.</span></td></tr></tbody><tbody class="xRowGroup"><tr><td><span class="xSecondary">Activated PTT</span></td><td><span class="xLabel">Ordered On: </span><span class="content_span">12-Jul-2024</span></td><td/></tr><tr ID="_45b6abe8-4047-49e5-8056-37fd56a5861c"><td><span class="xSecondary xContentWrapping">12-Jul-2024 08:04</span></td><td><span class="xSecondary">Activated PTT</span><span class="xSecondary"> 32</span><span class="xSecondary"> s</span><span class="xSecondary"> (Normal)</span></td><td><content><span class="xLabel xSecondary">Range: </span><span class="xSecondary">25</span><span class="xSecondary"> s</span><span class="xSecondary"> - </span><span class="xSecondary">38</span><span class="xSecondary"> s</span><br/></content><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">Therapeutic heparin range is 58-92 seconds.</span></td></tr></tbody></table></div><h3><a name="id9" href="#toc">Vital Signs</a></h3><div><table class="xBorderBottom"><colgroup><col width="40%"/><col width="20%"/><col width="40%"/></colgroup><tbody class="xRowGroup"><tr><td><span class="content_span">12-Jul-2024 08:32</span></td><td/><td/></tr><tr ID="_6f24e73f-d866-4848-820a-33362007ddca"><td/><td><content><span class="xSecondary">Pulse </span><span class="xSecondary">64</span></content></td><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">64</span></td></tr><tr ID="_d44ddfd4-f5e3-48f6-910c-2cfdc8d1c1b8"><td/><td><content><span class="xSecondary">Respiratory Rate </span><span class="xSecondary">16</span></content></td><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">16</span></td></tr><tr ID="_4f124821-c1a4-41a5-9311-640bde6f4e36"><td/><td><content><span class="xSecondary">TEMP FAHRENHEIT </span><span class="xSecondary">97.3</span><span class="xSecondary"> f </span></content></td><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">97.3</span></td></tr><tr ID="_ae0aa92a-5ec9-422b-b144-d5924c976a45"><td/><td><content><span class="xSecondary">O2 SAT </span><span class="xSecondary">99</span><span class="xSecondary"> % </span></content></td><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">99</span></td></tr><tr ID="_0cedaee8-424d-4ced-afaf-133db7b14295"><td/><td><content><span class="xSecondary">BP Systolic </span><span class="xSecondary">176</span><span class="xSecondary"> mm[Hg] </span></content></td><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">176</span></td></tr><tr ID="_c6135cbe-e84b-4302-b5e2-7d746c0bc9d4"><td/><td><content><span class="xSecondary">BP Diastolic </span><span class="xSecondary">79</span><span class="xSecondary"> mm[Hg] </span></content></td><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">79</span></td></tr><tr ID="_dc147690-036d-4fe1-b34e-9d33b013a38a"><td/><td><content><span class="xSecondary">Height </span><span class="xSecondary">6.08333334</span><span class="xSecondary"> [ft_us] </span></content></td><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">6</span></td></tr><tr ID="_a669dee0-fd83-420d-bd36-43ec953741b9"><td/><td><content><span class="xSecondary">Weight </span><span class="xSecondary">91.818</span><span class="xSecondary"> kg </span></content></td><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">91.818</span></td></tr></tbody><tbody class="xRowGroup"><tr><td><span class="content_span">12-Jul-2024 08:29</span></td><td/><td/></tr><tr ID="_4f9aa3c9-ded6-4343-8ada-b74eed4893a3"><td/><td><content><span class="xSecondary">Height </span><span class="xSecondary">6.08333334</span><span class="xSecondary"> [ft_us] </span></content></td><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">6</span></td></tr><tr ID="_51de9a29-847d-456d-903e-558f80e26d18"><td/><td><content><span class="xSecondary">Weight </span><span class="xSecondary">91.818</span><span class="xSecondary"> kg </span></content></td><td><span class="xLabel xSecondary">Comments: </span><span class="xSecondary">91.818</span></td></tr></tbody></table></div><h3><a name="id10" href="#toc">Encounters</a></h3><div><table><colgroup><col width="40%"/><col width="20%"/><col width="40%"/></colgroup><tbody class="xRowGroup"><tr ID="_ac7151d7-723d-4670-ad86-63463802a3a4"><td><span class="content_span">short stay</span><br/><content><span class="xLabel xSecondary">Encounter Reason:</span><span class="xSecondary">SOB</span></content><br/><content><span class="xSecondary xLabel">Encounter Diagnosis:</span><span class="xSecondary">Ischemic cardiomyopathy</span><span class="xSecondary">, </span><span class="xSecondary">Hypertensive heart disease with heart failure</span><span class="xSecondary">, </span><span class="xSecondary">Chronic systolic (congestive) heart failure</span><span class="xSecondary">, </span><span class="xSecondary">Unspecified atrial fibrillation</span><span class="xSecondary">, </span><span class="xSecondary">Hyperlipidemia, unspecified</span><span class="xSecondary">, </span><span class="xSecondary">Atherosclerotic heart disease of native coronary artery without angina pectoris</span><span class="xSecondary">, </span><span class="xSecondary">Presence of automatic (implantable) cardiac defibrillator</span><span class="xSecondary">, </span><span class="xSecondary">Asymptomatic human immunodeficiency virus [HIV] infection status</span><span class="xSecondary">, </span><span class="xSecondary">Long term (current) use of antithrombotics/antiplatelets</span><span class="xSecondary">, </span><span class="xSecondary">Presence of prosthetic heart valve</span><span class="xSecondary">, </span><span class="xSecondary">Long term (current) use of anticoagulants</span><span class="xSecondary">, </span><span class="xSecondary">Long term (current) use of aspirin</span><span class="xSecondary">, </span><span class="xSecondary">Presence of aortocoronary bypass graft</span><span class="xSecondary">, </span><span class="xSecondary">Family history of ischemic heart disease and other diseases of the circulatory system</span><span class="xSecondary">, </span><span class="xSecondary">Encounter for adjustment and management of automatic implantable cardiac defibrillator</span></content></td><td><span class="xSecondary">12-Jul-2024 07:00 </span><span class="xLabel xSecondary"> To </span><span class="xSecondary">12-Jul-2024 07:00</span><br/><span class="xSecondary">Satija Sameer MD (Attending)</span><br/><span class="xSecondary">Westside Reg</span><br/></td><td><span class="xLabel">Discharge Disposition: </span><span class="xSecondary">Discharged to home or self care (routine discharge)</span><br/></td></tr><tr ID="_c0184c3a-3db9-4b17-b8d9-cd574d2f8acb"><td colspan="3"><span class="xIndent"> •</span><content class="xSecondary xContentWrapping"><span class="content_span">Satija Sameer MD</span><span class="xLabel"> - </span><span class="content_span">12-Jul-2024</span><br/><span class="content_span">                        HCA Florida Westside Hospital
                           8201 W Broward Blvd
                         Plantation, Florida 33321
                         OPERATIVE OR PROCEDURE REPORT

PATIENT'S NAME: MANNELLINO,DOMINICK           UNIT NO: W000313546
DOB: 10/03/46                              ACCOUNT NO: W00021284755
ATT. PHYSICIAN:Satija,Sameer  MD              PT TYPE: DEP SDC
ADMISSION DATE:                               ROOM NO:


SURGEON:  Sameer Satija, MD

DATE OF PROCEDURE:  07/12/2024

PROCEDURE:  Biventricular defibrillator generator exchange.

INDICATIONS FOR PROCEDURE:  This is a very pleasant 77-year-old male with
chronic systolic heart failure.  He has a biventricular defibrillator that was
placed on December 18, 2012.  He had original RA and RV leads placed on
November 12, 2007 with the upgrade in 2012.  His device is now at elective
replacement indicator.

DESCRIPTION OF PROCEDURE:  The patient presented to the EP lab in a fasting
condition.  He was prepped and draped in the usual fashion.  Preoperative
antibiotics were administered.  He was sedated by the anesthesia team.  I
discovered unfortunately that the Medtronic vendor who was present for the case
did not have an appropriate device with the right header for this patient's
lead systems, specifically the patient needed a DF1 LV4 header and Medtronic
did not have one.  I therefore had to change out to an Abbott device as the
Abbott vendor had an appropriate device readily available.  I infiltrated the
chronic scar with lidocaine and opened with a #10 blade.  Using blunt
dissection and electrocautery, I freed up the chronic device.  I then checked
the leads.  The atrial lead is a Medtronic 5076 lead, 52 cm length, serial
#PJN1463368, date of implant, November 12, 2007.  P-wave measures 0.5,
impedance 540 ohms.  No threshold was obtained as the patient was in atrial
fibrillation.  Right ventricular lead is a Medtronic 6947 lead, serial
#TDG178861V, date of implant, November 12, 2007.  R-wave measured 6.0,
impedance 360 ohms, threshold 0.5 at 0.5 msec.  The LV lead is a Medtronic 4296
lead, serial #RRA537574B, date of implant, December 18, 2012, impedance is 450
ohms, threshold 1.6 at 0.5 msec.  All 3 leads were attached to a new Abbott
biventricular defibrillator, model #3357, serial #5555307.  I placed the device
in the pocket.  I closed the pocket with 2 layers of absorbable sutures and
overlying glue and Steri-Strips.

Sameer Satija, MD

SS/Aquity
DD:  07/16/2024 10:46
DT:  07/16/2024 16:29
Job #:  466759 / 1034815581
Authenticated by Sameer Satija On 07/23/2024 01:10:55 PM






PATIENT NAME: MANNELLINO,DOMINICK            ACCOUNT #: W00021284755



Electronically Signed by Sameer Satija, MD on 07/23/24 at 0110






















































PATIENT NAME: MANNELLINO,DOMINICK            ACCOUNT #: W00021284755</span></content></td></tr></tbody></table></div><h3><a name="id11" href="#toc">Plan of Treatment</a></h3><div>Plan of treatment may be documented in an alternate section</div><h3><a name="id12" href="#toc">Health Concerns</a></h3><div>Health concerns may be documented in an alternate section</div><h3><a name="id13" href="#toc">Goals</a></h3><div>Goals may be documented in an alternate section</div><h3><a name="id14" href="#toc">Assessments</a></h3><div>No assessment information available</div><h3><a name="id15" href="#toc">Medical Equipment</a></h3><div>No implantable device information available</div><br/><br/></body></html>